Navigation Links
SynCardia Hits Record-Setting 150th Implant of the Total Artificial Heart in 2013
Date:12/11/2013

TUCSON, Ariz., Dec. 11, 2013 /PRNewswire/ -- SynCardia Systems, Inc. continues to set records with the implantation of the year's 150th SynCardia temporary Total Artificial Heart on Nov. 26, 2013. With almost three weeks left in 2013, SynCardia projects beating the 2012 record of 125 implants by 35 additional Total Artificial Hearts, the most patients ever implanted in one year.

(Photo: http://photos.prnewswire.com/prnh/20131211/LA31265)

"The record we are setting in 2013 for SynCardia Total Artificial Heart implants nearly doubles what was then our 2011 record-breaking year of 81 implants," says SynCardia CEO and President Michael P. Garippa.

The new record includes the first patient in the Gulf South Region, the first Nebraska and Florida patients, an Indiana patient who became the 1,200th implant worldwide and the youngest patient, 16, ever to receive a SynCardia Heart powered by the Freedom® portable driver.

This year, the top 10 SynCardia Certified Centers averaged more than eight implants per center. Leading centers include EJK Duisburg, Germany; La Pitié-Salpêtriére in Paris, France; Ege University in Izmir, Turkey, and seven SynCardia Certified Centers in the United States, including Cedars-Sinai Heart Institute and University of Rochester Medical Center.

The Nebraska Medical Center was a leader for implants by first-year SynCardia Certified Centers.

"Surgeons and patients around the world are recognizing the life-saving benefits of the SynCardia Total Artificial Heart," says Garippa. "The SynCardia Heart is becoming the standard of care for end-stage biventricular heart failure." Garippa joined SynCardia as president in July 2010 and became CEO, as well, in May 2011.

The SynCardia Heart is the world's first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart. It is used as a bridge to transplant to a donor heart. Similar to a heart transplant, the SynCardia device replaces both failing heart ventricles and the four heart valves, which eliminate the source and symptoms of end-stage biventricular (both sides) heart failure.

Unlike a donor heart, the SynCardia Heart is immediately available at 93 SynCardia Certified Centers. Thirty-five other medical centers are in the process of certification.

The Freedom portable driver, weighing 13.5 pounds, allows patients to leave the hospital to live at home and their communities. It provides them the freedom to exercise, comfortably sleep at home, enjoy a home-cooked meal and get out in the community, all of which help them get stronger for an eventual donor heart transplant.

CAUTION - The Freedom portable driver is an investigational device, limited by United States law to investigational use.

About the SynCardia temporary Total Artificial Heart
SynCardia Systems, Inc. (Tucson, AZ) is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart, the SynCardia Total Artificial Heart is currently approved as a bridge to transplant for people suffering from end stage heart failure affecting both sides of the heart (biventricular failure). There have been more than 1,250 implants of the Total Artificial Heart, accounting for more than 335 patient years of life on the device.

Similar to a heart transplant, the SynCardia Total Artificial Heart replaces both failing heart ventricles and the four heart valves. It is the only device that eliminates the symptoms and source of end stage biventricular failure. Unlike a donor heart, the Total Artificial Heart is immediately available at 93 SynCardia Certified Centers worldwide with 35 others in the process of certification.

The Total Artificial Heart provides immediate, safe blood flow of up to 9.5 liters per minute through each ventricle. This high volume of blood flow helps speed the recovery of vital organs, helping make the patient a better transplant candidate.

Forbes Ranks SynCardia #69 Among "America's Most Promising Companies"
In its February 2013 issue, Forbes selected SynCardia as one of "America's Most Promising Companies" for the second consecutive year. On the list of 100 privately held, high-growth companies with bright futures, SynCardia was selected #69, moving up eight spots from its #77 ranking last year. See the full list of SynCardia Awards & Recognition.

For additional information, please visit: http://www.syncardia.com
Like SynCardia on Facebook
Follow SynCardia on Twitter – @SynCardia
Connect with SynCardia on LinkedIn


'/>"/>
SOURCE SynCardia Systems, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. SynCardia Posts Record Revenue and Profit in Q1 2012
2. 3 Pediatric Centers that Offer SynCardia Total Artificial Heart Named in Top 10 for "Best Childrens Hospitals"
3. 1st SynCardia Total Artificial Heart Implant Performed in New England
4. 50% of U.S. News & World Reports "Best Hospitals" for Cardiology & Heart Surgery Making the SynCardia Total Artificial Heart Part of Their Toolbox
5. SynCardias Record-Setting Q2 Marks 5th Consecutive Profitable Quarter
6. EJK Duisburg Becomes One of the Most Active SynCardia Certified Centers in Europe
7. SynCardia Total Artificial Heart Patient Featured in U.S. News & World Reports "Best Hospitals" Issue
8. 1st SynCardia Total Artificial Heart Patient Discharged from Ankara University in Turkey
9. University of Washington Leads All SynCardia Certified Centers with 10 Implants of the Total Artificial Heart in 2012
10. Forbes Ranks SynCardia Among "Americas Most Promising Companies" for Second Straight Year
11. SynCardia Total Artificial Heart Patient with End-Stage Renal Failure Recovers Kidney Function after Two Months of Support
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... Research and Markets has announced the addition of ... report to their offering. ... The report also analyses the market by the following Technology Types: Label-Free ... the US, Canada , Japan , ... Latin America , and Rest of World. Annual ...
(Date:12/9/2016)... aTyr Pharma, Inc. (Nasdaq: LIFE ), a biotherapeutics company ... severe, rare diseases, today announced that senior management will participate in ... Conference at the InterContinental Barclay Hotel in New York ... ET. About aTyr Pharma ... aTyr Pharma is engaged in the ...
(Date:12/9/2016)... , Dec. 9, 2016  Forge Therapeutics, Inc. ... (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) to ... for the treatment of bacterial infections including those ... recognized as an attractive antibacterial target for more ... of suitable chemical starting points has hampered its ...
Breaking Medicine Technology:
(Date:12/9/2016)... Northern Kentucky - Cincinnati, Ohio (PRWEB) , ... ... ... leader in the production of miniature, folded, pharmaceutical inserts and outserts. As ... & Serialization Device. This addition will enable Flottman to individually code professional ...
(Date:12/9/2016)... , ... December 09, 2016 , ... ... celebrated its 10th anniversary with the grand opening of the Sober College Robert ... event spanned two days, December 2-3, and was attended by an overwhelming amount ...
(Date:12/9/2016)... ... December 09, 2016 , ... The Holy Name Medical Center ... NY, on December 3rd, to benefit Holy Name Medical Center's programs and services. ... raised over $1 million - the largest event in the Center's history, both ...
(Date:12/9/2016)... ... 09, 2016 , ... The Pennsylvania Athletic Trainers’ Society (PATS) ... summer of 2016. The program was made possible by a Pennsylvania Department of ... Health and Human Services Administration. The broadcast, Use Your Head: Properly Managing ...
(Date:12/8/2016)... ... 2016 , ... After enjoying record-breaking attendance at its last ... 33rd Annual Issues & Research Conference, March 2-3, 2017, at the Westin ... is “Persistent Challenges and New Opportunities: Using Research to Accelerate the Dialogue." 2016 ...
Breaking Medicine News(10 mins):